Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT04433455
Recruiting Observational

Influencing Factors of Cerebrovascular Disease and Cognition in Hemodialysis Patients

NCT04433455 · tracked via the Priya Life Science China tracker
Sponsor
Huashan Hospital
Phase
Observational
Started
2020-06-01
Last updated
2026-09-23

Condition(s) studied

HemodialysisCognitive ImpairmentCerebrovascular Disorders

Study summary

In this observational study, the investigators evaluate the influencing factors of cerebrovascular disease and cognition in hemodialysis patients.

Eligibility

Sex
ALL
Min age
50 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: 1. maintenance hemodialysis patients who are younger than 85 years old and older than 50 years old, regardless of gender 2. dialysis vintage is greater than 3 months; Exclusion Criteria: 1. Those with severe infection and anemia (Hb \<60g / L); 2. Those with severe mental illness, metabolic diseases and immune system diseases; 3. Patients with abnormal liver function

Primary outcome measure(s)

  • cerebrovascular disease — 5 years
    Magnetic resonance images will be used to determine the severity of white matter hyperintensity, using the Scheltens scale. Score 2 or more is abnormal.

Trial sites (1)

FacilityCityRegionStatus
Huashan Hospital Shanghai Shanghai Municipality Recruiting

More Huashan Hospital trials in China

Real-World Study of Enarodustat for Anemia in Non-Dialysis CKD Patients Recruiting
Bilateral Single-Electrode VO Combined With STN-DBS for Treating Meige Syndrome Recruiting
The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function Recruiting
The Role of B7-H4 in Tumor Vaccine Recruiting
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China Recruiting

Other trials for the same condition

A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China Recruiting
Characteristics of Papez Loop Neural Network in T2DM （Type 2 Diabetes Mellitus） Recruiting
Statins for Treatment of Primary Intracerebral Hemorrhage Recruiting
The Beijing Longitudinal Disability Survey in Community Elderly Recruiting
Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04433455 on ClinicalTrials.gov ↗ ← All trials in China